RxSight Stock

rxsight.comHealthcareFunding to Date: $179.84MM

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Register for Details

For more details on financing and valuation for RxSight, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for RxSight.

Register Today

Team

Management Team

Shelley Thunen
Chief Financial Officer
Robert Grubbs
Co-Founder
Ronald Kurtz MD
Chief Executive Officer, President & Board Member
Christian Sandstedt Ph.D
Vice President, Optics Research & Development
Matthew Haller Ph.D
Chief Technology Officer
Eric Weinberg
Chief Commercial Officer

Board Members

Christopher Cox JD
Werner Wolfen
Javier Perez-Sala
Bruce Robertson Ph.D
H.I.G. BioHealth Partners
J. Corley
Ronald Kurtz MD
Juliet Bakker
Longitude Capital
Jan Bonel
Daniel Schwartz
William Link Ph.D
Flying L Partners
Joseph Devivo
James Adler

Other companies like RxSight in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

Venture investors are providing $69 million to Calhoun Vision Inc. and betting that its technology will make it stand out in a crowded market for artificial lenses used in cataract patients.